All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On July 14, 2020, the U.S. Food and Drug Administration (FDA) granted an orphan drug designation for PXS-5505.
Myelofibrosis is a rare hematological disease where bone marrow is gradually replaced by fibrotic tissue eventually leading to bone marrow failure. Patients with myelofibrosis have limited therapeutic options and a poor prognosis. Lysyl oxidases (LOX) are involved in cross-linking extracellular matrix proteins and have been shown to be upregulated in patients with myelofibrosis.1 PXS-5505, a pan-LOX inhibitor, is currently under development for the treatment of myelofibrosis. It is an oral compound that has demonstrated a well-tolerated safety profile, as well as good pharmacokinetic and pharmacodynamic properties in a phase I study. Also, in vivo models have demonstrated significant reductions in fibrotic burden.2
Read here for more information on myelofibrosis.
Subscribe to get the best content related to MPN delivered to your inbox